Specify a stock or a cryptocurrency in the search bar to get a summary
Shenzhen Chipscreen Biosciences Co
688321Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines for the treatment of human diseases in five therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. It is developing chidamide, a subtype-selective benzamide inhibitor of histone deacetylase (HDAC) primarily targeting subtypes 1, 2, 3 of class I HDAC; chiglitazar, a new-generation insulin sensitizing candidate drug for the treatment of type 2 diabetes mellitus; chiauranib, an aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor; and CS12192, a highly selective JAK3 kinase inhibitor. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is headquartered in Shenzhen, China. Address: Zhigu Industrial Park, Shenzhen, China, 518057
Analytics
WallStreet Target Price
236.36 CNYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 688321
Dividend Analytics 688321
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 688321
Stock Valuation 688321
Financials 688321
Results | 2019 | Dynamics |